14.31 0.00 (0.00%)
After hours: 4:41PM EDT
|Bid||13.69 x 4000|
|Ask||14.47 x 800|
|Day's Range||13.22 - 14.91|
|52 Week Range||9.44 - 20.87|
|Beta (3Y Monthly)||3.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alder Biopharmaceuticals Inc NASDAQ NMS:ALDRView full report here! Summary * Bearish sentiment is moderate and increasing Bearish sentimentShort interest | NegativeShort interest is moderately high for ALDR with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on March 8. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold ALDR had net inflows of $739 million over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
An RBC Capital Markets analyst is "head over heels" for five biotech stocks, two with high Relative Strength Ratings. In afternoon action in the stock market, biotech stocks inched up.
Molina Healthcare (MOH) is expected to gain in Q4 on the back of membership strength and its streamlining initiative. However, the same might be partly offset by a dismal Marketplace business.
Alder BioPharmaceuticals (ALDR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MacroGenics' (MGNX) shares rise as the FDA lifts partial clinical hold on its early-stage cancer candidate, MGD009, placed in December last year.
Alder Biopharmaceuticals could eventually capture 15%-20% of the market for migraine prevention, an analyst said Monday, suggesting the biotech stock might be a good fit for giant Biogen.
At Insider Monkey, we pore over the filings of more than 700 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we’ve gathered as a result gives us access to a wealth of collective knowledge based on these firms’ portfolio holdings as of September 30. In […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 11) Imprimis Pharmaceuticals Inc (NASDAQ: IMMY ) OvaScience ...
On a per-share basis, the Bothell, Washington-based company said it had a loss of 91 cents. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...